annalise.ai: Revolutionizing Critical Care Radiology with AI-Powered Decision Support

annalise.ai is a cutting-edge medical imaging AI company dedicated to enhancing diagnostic accuracy and efficiency in critical care settings. Specializing in radiology decision support, its AI solutions are designed for clinical use by radiologists and healthcare providers, offering rapid, reliable detection of life-threatening conditions in non-contrast head CT and chest X-ray studies. Built on a foundation of over 1 million imaging studies and more than 280 million expert labels from at least three radiologists per case, annalise.ai delivers clinically validated, FDA 510(k)-cleared tools that integrate seamlessly into existing workflows. With a focus on real-world impact, the platform improves report turnaround times by up to 39%, boosts diagnostic accuracy by 45%, and helps prioritize urgent cases through its Critical Care AI feature. Its innovative solutions, including Annalise Enterprise CTB and CXR, are CE marked as Class IIb medical devices and are already deployed in leading healthcare institutions across Australia, the UK, the U.S., India, Singapore, and the EU. The company’s clinician-driven design ensures trust, transparency, and integration into daily practice, while features like Annalise Reporting generate complete, editable, hallucination-free draft reports in 12 languages—streamlining workflows and reducing human error. annalise.ai’s commitment to safety, quality, and innovation is backed by strong partnerships, including with Nuance Communications (a Microsoft Company), and recognition through awards and peer-reviewed research.

Key Features:

• Annalise Enterprise CTB: FDA 510(k)-cleared AI for non-contrast head CT, detecting up to 130 radiological findings in under 2 minutes.
• Annalise Enterprise CXR: FDA 510(k)-cleared AI for chest X-rays, identifying up to 124 findings in under 20 seconds with a confidence bar.
• Critical Care AI: Flags 11 time-sensitive findings to prioritize urgent cases, improving time-to-care and report turnaround.
• Annalise Reporting: Automated, editable draft reporting for CXR and CTB studies, reducing workload and bias while supporting 12 languages.
• Multi-Image Analysis: Analyzes up to three images per study, correlating findings across different views for enhanced accuracy.
• Workflow Integration: Seamlessly integrates with PACS, RIS, and reporting worklists for real-time clinical use.
• NTAP Eligibility: Annalise Obstructive Hydrocephalus is eligible for New Technology Add-On Payment reimbursement in the U.S.
• Clinician-Driven Design: Developed with input from over 150 radiologists, ensuring practical, trustworthy deployment.
• Global Deployment: Proven in real-world environments including NHS Epsom St. Helier, NHS Grampian, Parkway Radiology, and Mass General Brigham.
• High Performance: Demonstrated >80% sensitivity and specificity in detecting critical findings like pneumothorax and tension pneumothorax.
• Breakthrough Device Status: Recognized by the FDA as a Breakthrough Device for obstructive hydrocephalus detection.
• Comprehensive Validation: Backed by peer-reviewed research and case studies published in journals like the Journal of the American College of Radiology and Radiology.

Pricing: annalise.ai operates on a subscription-based model, tailored for healthcare institutions and radiology departments, with pricing available upon request through a consultation with their experts.

Conclusion: annalise.ai is a trusted, clinically validated AI partner for radiologists worldwide, delivering fast, accurate, and life-saving insights in critical care imaging—transforming radiology workflows with intelligence that enhances both patient outcomes and clinician efficiency.